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Abstract 
  BACKGROUND: The polymorphisms of cytochrome P450 2C19 (CYP2C19) gene are major 
prognostic factors for the response to clopidogrel therapy in patients with coronary artery 
diseases (CAD). The CYP2C19*2 is the most important allele responsible for resistance to 
clopidogrel therapy. This study examined CYP2C19 gene polymorphism (CYP2C19*1 and *2) in 
Iranian patients. 
 METHODS:  This cross-sectional study was performed on 43 Iranian patients with CAD who 
underwent percutaneous coronary intervention (PCI) and received drug-eluted stents (DES). 
CYP2C19 polymorphisms were assessed using real time PCR and frequency of CYP2C19*1 and 
CYP2C19*2 were determined, and then homo- or heterozygous state of genes was detected by 
Melt Curve Analysis method. 
 RESULTS: Forty three patients (mean age = 58.8 ± 10.0 years, 79.1% male) participated in this 
study. CYP2C19*1/CYP2C19*1 genotype was observed in 31 (72.1%) of participates, 
CYP2C19*1/CYP2C19*2 genotype in 10 (23.3%), and CYP2C19*2/CYP2C19*2 genotype in 2 
patients (4.7%). The frequency of CYP2C19*2 allele in the sample was 27.9%. 
  CONCLUSION: This study demonstrated a high prevalence of CYP2C19*2 gene polymorphism 
in Iranian patients. Further studies with larger samples or longitudinal are required to 
determine the effects of this polymorphism on the prognosis of CAD patients in our population. 
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Introduction 
Despite considerable improvements in preventive 
programs and increasing access to specialized medical 
care, atherosclerosis and its subsequent complications, 
such as ischemic heart diseases, have remained the 
leading causes of mortality all over the world, 
especially in developing countries.1,2 In Iran, coronary 
artery disease (CAD) is still the most important cause 
of mortality, with nearly 40% of all deaths, and also 
the most important cause of morbidity.3,4 Reperfusion 
of the coronary arteries by surgical or medical 
interventions is the first-line treatment in ischemic 
heart disease, which significantly reduce the mortality 
and morbidity in patients with CAD. The treatment 
methods are the administration of fibrinolytic drugs 
or surgical intervention including coronary artery 
bypass surgery (CABG) and percutaneous coronary 
intervention (PCI). Indeed, PCI is the treatment of 
choice for acute myocardial infarction (MI), if it is 
done on time.5,6   A. Akhlaghi, Sh. Shirani, N. Ziaie, O. Pirhaji, M. Yaran, G. Shahverdi, N. Sarrafzadegan, A. Khosravi, E. Khosravi 
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  Currently, coronary artery stents, particularly   
drug-eluting stents (DES), are used in the majority of 
patients who undergo PCI, which results in a 
significant decrease in the rate of thrombosis and 
restenosis in coronary arteries. It can reduce acute 
closure of the artery from 2 to 10 percent to less than 
1 percent and restenosis from 30 to 40 percent to less 
than 10 percent.7-9 However, stent thrombosis is a 
rare but serious complication that can occur in either 
acute (in 24 hours), subacute (in 30 days) or late (in 
one year) after stent placement. Many studies have 
been conducted on the prevention of stent 
thrombosis with antiplatelet therapy. The American 
Society of Cardiology (ASC) guideline has 
recommended the administration of clopidogrel, in 
combination with aspirin, in patients using bare metal 
stents (BMS) for at least one month (and up to 12 
months in recent studies10 and in patients using DES 
stents for at least 12 months.11 
  Clopidogrel is a pro-drug agent that, after 
becoming an active metabolite, selectively blocks 
ADP dependent platelet activation and aggregation. 
The drug requires the enzyme cytochrome P450 2C19 
(CYP2C19) function for its activation and antiplatelet 
effects. In some patients (with different prevalence in 
different communities), clopidogrel has no antiplatelet 
effect or its effect is reduced. The responsiveness to 
clopidogrel is determined by genetic and acquired 
factors, and is one of the important factors in stent 
thrombosis and cardiac events after the stent 
placement in patients with CAD.12 Single nucleotide 
polymorphisms of CYP2C19 that reduce the activity 
of this enzyme are among the causes of racial 
differences in response to the antiplatelet effects of 
clopidogrel.12 The presence of CYP2C19*2 allele 
decreases the response to antiplatelet effects of 
clopidogrel.13 According to a meta-analysis, the risk of 
restenosis in the stent place in people who had at least 
one non-functional allele were 1.77 times more than 
those who were carrying two functional alleles.14 
Furthermore, according to another meta-analysis, the 
major cardiovascular events in individuals carrying the 
allele CYP2C19*2 are 30% more than non-carriers. In 
addition, they had a higher risk for mortality (OR = 
1.79) and stent thrombosis (OR = 3.45).15 
  According to recent review studies, initial 
individualize treatment based on the CYP2C19 
genotype is controversial.13,14,16 However, considering 
the importance of prevention of complications of 
stent thrombosis, the study of CYP2C19 
polymorphisms in each population can be suggestive 
for the prognosis of the response to the treatment 
and the provisions needed for patients undergoing 
PCI. Considering that there was no report 
determining the prevalence of CYP2C19 
polymorphisms in patients undergoing PCI in the 
Iranian population, this study was conducted to 
determine the prevalence of this gene polymorphism 
for ethnically Iranian patients. 
Materials and Methods 
This cross-sectional study was performed on 
ethnically Iranian patients who were diagnosed with 
CAD and undergone coronary angioplasty and 
stenting (DES) in Shahid Chamran, Sepahan, and Sina 
hospitals in Isfahan (IRAN) in 2011. Considering the 
prevalence of clopidogrel resistance as 30% and the 
acceptable error of 0.14, 43 patients were randomly 
selected from the centers. The study was approved 
by the Medical University of Isfahan Ethics 
Committee and written informed consent was 
obtained from all participants. To determine the 
genotype of the patient's blood sample was taken, 
and Genomic DNA extracted from 200 micro liter 
of blood using the High Pure PCR Template 
Preparation Kit. The CYP2C19*2 and CYP2C19*1 
genotypes were proliferated with specific PCR kits 
using Real-Time PCR Corbett Research 6600 in the 
laboratory. Melt Curve Analysis method was used 
for distinguishing the homozygous and heterozygous 
types of the genes. The data were analyzed by the 
SPSS version 16.0. 
Results 
In this study, 43 patients (mean age = 10.0 ± 58.4 
years; 82% male) participated. The frequency of risk 
factors for heart disease was as fallowed; hypertension 
= 18 patients (47.3%), diabetes = 13 patients (34.2%), 
dyslipidemia = 14 patients (36.8%), and smoking = 9 
patients (23.6%). 
  The prevalence of genotypes was as fallowed: 
CYP2C19*1/CYP2C19*1 = 31 patients (72.1%), 
CYP2C19*1/CYP2C19*2 = 10 patients (23.3%), and 
CYP2C19*2/CYP2C19*2 = 2 patients (4.7%)   
(Figure 1). So the relative frequency of CYP2C19*2 
allele in the study sample was 27.9%. 
Discussion 
Polymorphisms of CYP2C19 and CYP2C19*2 allele 
are major determinants of prognosis after MI in 
patients treated with clopidogrel. According to 
studies, the incidence of CYP2C19*2 allele in East 
Asian societies is more than Western societies. For 
example, in a study conducted in Korea on 2,146 
patients receiving DES, 47% had at least one 
CYP2C19*2 allele. Patients were followed for 12 
months and results showed that deaths due to heart 
failure, MI, and stent thrombosis, were significantly Cytochrome p450 2c19 polymorphism in Iranian 
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Figure 1. CYP2C19 genotypes in Iranian patients with CAD 
 
higher in patients who were the carriers of 
CYP2C19*2 allele compared with non-carriers   
(2.0% vs. 0.8%).17 According to a study conducted in 
Lebanon, in healthy population, the relative frequency 
of alleles CYP2C19*2 and CYP2C19*3 were 
respectively 13% and 3%.18 In our study, the overall 
relative frequency of CYP2C19*2 alleles was 26.3% 
and the relative frequency of homozygous was 5.3% 
for this allele. In one study conducted in Tehran 
(Iran) by Zendehdel et al, on patients with 
gastroesophageal reflux disease under treatment with 
omeprazole, frequency of CYP2C19*2 alleles was 
13.4% and the relative frequency of homozygous was 
1.3% for this allele.19 In another study conducted on 
general healthy population of Tehran Zand et al 
reported the frequency of CYP2C19*2 allele as 25% 
and the relative frequency of homozygous as 3%.20 
The difference among these studies could be due to 
difference in the studied populations as in our study 
and the study by Zand et al, the sample was from 
specific patients while in the other study sampling was 
done from the general population.20 
  Considering that the presence of non-functional 
CYP2C19 polymorphism determines the prognosis of 
response to the treatment with clopidogrel, some 
researchers recommended that treatment choice 
should be based on patient's genotype. However, 
according to the new review studies, the 
recommendation of treatment initially based on the 
CYP2C19 genotype is controversial.13,14,16 It is 
important to know that most of these studies have 
been done on western populations and the results of 
similar studies in Asian populations might be 
different. This issue is more important when other 
determining factors of response to treatment with 
clopidogrel such as drug interactions would be 
considered. While patients on clopidogrel-aspirin dual 
antiplatelet therapy usually require treatment with 
proton pump inhibitors (PPI), statins, and other 
medications, the drugs are to reduce the activity of 
CYP2C19. Thus, in the patients with reduced activity 
of the enzyme CYP2C19, because of being the 
carriers of CYP2C19*2 allele, selecting a drug with 
less interaction with this enzyme become more 
important.21 According to a large cohort study in 
French on 2744 patients who were using clopidogrel 
and PPI at the same time after MI, the results showed 
that the co-administration of clopidogrel and PPI did 
not increase the risk of cardiovascular events or 
mortality and the results did not change with regard 
to the type of PPI and CYP2C19 genotypes, though 
the results of this cohort study showed that the 
increased risk in patients carrying the two non-
functional alleles cannot be ruled out.22 However, due 
to the higher prevalence of non-functional CYP2C19 
alleles in East Asian populations, drug interactions in 
these communities may have a different effect. As the 
results of a large study in Taiwan showed, 
simultaneous use of clopidogrel and PPI is associated 
with increased mortality (hazard ratio = 1.65).23   A. Akhlaghi, Sh. Shirani, N. Ziaie, O. Pirhaji, M. Yaran, G. Shahverdi, N. Sarrafzadegan, A. Khosravi, E. Khosravi 
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  There are some studies on some strategies such as 
using higher doses of clopidogrel, adding or 
alternating the therapy with other antiplatelet drugs 
(e.g. ticagrelor and cilostazol),24 and using CYP2C19 
enzyme inducers (e.g. St. John's wort)25 in patients 
with non-functional alleles of CYP2C19. According 
to Cuisset et al study, increasing the doses of 
clopidogrel in patients undergoing PCI, who had not 
responded appropriately to the drug was effective in 
those who had no CYP2C19*2 allele.26 In the study of 
Park et al, cilostazol was added to clopidogrel-aspirin 
regimen and significantly reduced platelet activity in 
patients carrying the non-functional allele.27 However, 
no single strategy for carrier patients is yet 
recommended. Also, in selecting a cost-benefit 
treatment strategy, the prevalence of non-functional 
alleles in each population should be considered. 
  The results of this study on an Iranian population 
with CAD who underwent PCI and received DES 
showed that the overall relative frequency of 
CYP2C19*2 alleles is high. These results, mostly 
follows other studies in Asian populations and shows 
the higher prevalence of alleles responsible for 
clopidogrel resistance in our population than western 
populations. Further cohort studies with larger 
sampling and on different races are required to 
determine the effects of this polymorphism on the 
prognosis of CAD patients in our population. 
Limitations 
There are some limitations to our study. The 
prevalence of other non-functional CYP2C19 alleles 
were not studied, though the CYP2C19*2 is the 
most important allele responsible for resistance to 
clopidogrel therapy. Also, the response to 
clopidogrel treatment and the final outcome was 
reported in this study, which is now undergoing by 
following-up the patients for one year. 
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